Please login to the form below

telaprevir

This page shows the latest telaprevir news and features for those working in and with pharma, biotech and healthcare.

to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.

Access to new hep C treatments put under the spotlight

telaprevir). But NICE has not recommended the use of Daklinza-based regimens to treat patients with genotype 3 of the disease - which accounts for around 45% of all cases in England,
FDA approves four new medicines across multiple areas

and Vertex' Incivek (telaprevir).
J&J starts to feel biosimilar competition bite

toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
Top biotech firms saw sales jump in 2014

Dion added: “This drop was largely attributable to sliding sales of Incivek (telaprevir), Vertex's hepatitis C virus protease inhibitor, which fell by $442.3m compared with 2013, primarily as a
The end of hepatitis C?

The launch a few years ago of first-generation protease inhibitors to the pharmaco-therapeutic arsenal - Vertex' Incivek (telaprevir) and Merck &Co's Victrelis (boceprevir) - drastically improved success rates in some ... Merck &Co. III. paritaprevir.

More from news
Approximately 0 fully matching, plus 34 partially matching documents found.

Deal Watch table for November 2013

172. Vertex / Janssen. Royalty sale. Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica.
Interview: Cesar Rodriguez, Janssen

Rodriguez also references infectious diseases as a stronghold for the company, mentioning the victory for hepatitis C treatment telaprevir in the 2012 UK Prix Galien Innovative Product Award.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Senior Account Executive with progression to Account Manager, Me...: Excellent package

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Client Services Director – Medical Education Agency – North West...: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Add my company

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...